<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677118</url>
  </required_header>
  <id_info>
    <org_study_id>YP2008004</org_study_id>
    <nct_id>NCT00677118</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant
      chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced NPC,
      in order to evaluate the value of adjuvant chemotherapy in nasopharyngeal carcinoma (NPC)
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presented with non-keratinizing NPC and stage T3-4N1M0/TxN2-3M0 are randomly
      assigned to receive concurrent chemoradiotherapy plus adjuvant chemotherapy (investigational
      arm)or concurrent chemoradiotherapy (control arm). Patients in both arms receive radical
      radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy. Patients in the
      investigational arm receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1
      to 5) every four weeks for three cycles after completion of radiotherapy. Patients are
      stratified according to the treatment centers. The primary end point was failure-free
      survival (FFS). Secondary end points included overall survival (OS), distant failure-free
      survival (D-FFS), locoregional failure-free survival (LR-FFS), the initial response rates
      after treatments, toxic effects and treatment compliance. All efficacy analyses were
      conducted in the intention-to-treat population; the safety population included only patients
      who received their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>2-yr</time_frame>
    <description>Failure-free survival is calculated from the date of randomization to the date of the first failure at any site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, distant failure-free survival and locoregional failure-free survival</measure>
    <time_frame>2-yr</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause. For distant failure-free survival and locoregional failure-free survival analyses, the latencies to the first remote or local failure, respectively, are recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">506</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent and adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiotherapy plus adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin,fluorouracil</intervention_name>
    <description>Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.</description>
    <arm_group_label>Concurrent and adjuvant</arm_group_label>
    <other_name>Cisplatin and fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.</description>
    <arm_group_label>Concurrent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly histologically confirmed non-keratinizing carcinoma (according to
             World Health Organization (WHO) histologically type)

          2. Tumor staged as N2-3or T3-4N1 (according to 6th American Joint Committee on Cancer
             staging system)

          3. No evidence of distant metastasis (M0)

          4. Performance status: KPS ≥70

          5. With normal liver function test (Alanine Aminotransferase、Aspartate Aminotransferase
             ≤2.5×upper limit of normal)

          6. Renal: creatinine clearance ≥60ml/min

          7. Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥80g/L and platelet count
             ≥100000/μL

          8. Written informed consent

        Exclusion Criteria:

          1. WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.

          2. Age ≥70 or &lt;18

          3. With a history of renal disease

          4. Prior malignancy

          5. Previous chemotherapy or radiotherapy

          6. Patient is pregnant or lactating

          7. Unstable cardiac disease requiring treatment.

          8. Emotion disturbance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Ma, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2003 Jul 1;98(1):74-80.</citation>
    <PMID>12833458</PMID>
  </reference>
  <reference>
    <citation>Ma J, Mai HQ, Hong MH, Cui NJ, Lu TX, Lu LX, Mo HY, Min HQ. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1181-9.</citation>
    <PMID>11483327</PMID>
  </reference>
  <reference>
    <citation>Zhao C, Han F, Lu LX, Huang SM, Lin CG, Deng XW, Lu TX, Cui NJ. [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]. Ai Zheng. 2004 Nov;23(11 Suppl):1532-7. Chinese.</citation>
    <PMID>15566674</PMID>
  </reference>
  <reference>
    <citation>Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22.</citation>
    <PMID>12007936</PMID>
  </reference>
  <reference>
    <citation>Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1440-50.</citation>
    <PMID>15590175</PMID>
  </reference>
  <reference>
    <citation>Decker DA, Drelichman A, Al-Sarraf M, Crissman J, Reed ML. Chemotherapy for nasopharyngeal carcinoma. A ten-year experience. Cancer. 1983 Aug 15;52(4):602-5.</citation>
    <PMID>6683121</PMID>
  </reference>
  <reference>
    <citation>Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev. 1987;6(3):181-98. Review.</citation>
    <PMID>3319271</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, Morandi L, Zucali R, Pilotti S, Grandi C, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988 Sep;6(9):1401-10.</citation>
    <PMID>3047335</PMID>
  </reference>
  <reference>
    <citation>Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1238-44.</citation>
    <PMID>11955734</PMID>
  </reference>
  <reference>
    <citation>Frederick L. Greene, David L. Page, Irvin D. Fleming, et al: American Joint Committee on Cancer Staging Manual (ed 6). Philadelphia (PA): Lippincott, 2002.</citation>
  </reference>
  <reference>
    <citation>Freedman J, Furberg, C, DeMets D. Fundamentals of clinical trials. Springer-Verlag, NY, 1998.</citation>
  </reference>
  <reference>
    <citation>Chow, S.C., Shao, J., Wang, H. Sample Size Calculations in Clinical Research. New York: Marcel Dekker; 2003.</citation>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <name_title>Jun Ma</name_title>
    <organization>Sun Yat-sen University Cancer Center</organization>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Concurrent chemoradiotherapy</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

